CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Olmesartan medoxomil + hydrochlorothiazide

Last Updated: November 28, 2008
Result type: Reports
Project Number: SR0151-000
Product Line: Reimbursement Review

Generic Name: Olmesartan medoxomil + hydrochlorothiazide

Brand Name: Olmetec Plus

Manufacturer: Schering-Plough Canada Inc.

Therapeutic Area: Hypertension

Indications: Hypertension

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: May 27, 2009

Recommendation Type: List in a similar manner to other drugs in class